JP2016530889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530889A5 JP2016530889A5 JP2016542337A JP2016542337A JP2016530889A5 JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5 JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hbv
- cells
- cdrs
- huh7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 238000006471 dimerization reaction Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000012642 immune effector Substances 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 208000015181 infectious disease Diseases 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101000872838 Hepatitis B virus genotype C subtype adr (isolate China/NC-1/1988) Small envelope protein Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000013631 noncovalent dimer Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 106
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 53
- 230000000638 stimulation Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- 239000010432 diamond Substances 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 8
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 238000002784 cytotoxicity assay Methods 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184635.4 | 2013-09-16 | ||
| EP13184635 | 2013-09-16 | ||
| PCT/EP2014/069675 WO2015036606A1 (en) | 2013-09-16 | 2014-09-16 | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530889A JP2016530889A (ja) | 2016-10-06 |
| JP2016530889A5 true JP2016530889A5 (enExample) | 2019-04-11 |
| JP6599338B2 JP6599338B2 (ja) | 2019-10-30 |
Family
ID=49165642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542337A Active JP6599338B2 (ja) | 2013-09-16 | 2014-09-16 | Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10059767B2 (enExample) |
| EP (1) | EP3046938B1 (enExample) |
| JP (1) | JP6599338B2 (enExample) |
| CN (2) | CN105636982B (enExample) |
| CA (1) | CA2924252C (enExample) |
| ES (1) | ES2773306T3 (enExample) |
| RU (1) | RU2671089C2 (enExample) |
| WO (1) | WO2015036606A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747011C (en) | 2008-12-18 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| CN105636982B (zh) | 2013-09-16 | 2020-06-23 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） | 用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽 |
| CA2975660A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Trispecific binding molecules for treating hbv infection and associated conditions |
| CN106349391A (zh) * | 2015-07-17 | 2017-01-25 | 中国科学院深圳先进技术研究院 | Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用 |
| US10865232B2 (en) * | 2015-11-13 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-IG fusion protein for cancer immunotherapy |
| CN105505872B (zh) * | 2016-02-16 | 2019-01-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种致敏nk细胞的方法及组合物 |
| CN107129537A (zh) * | 2016-02-29 | 2017-09-05 | 北京赛诺泰生物科技有限公司 | 抗乙型肝炎病毒的免疫反应性细胞 |
| JP2019529499A (ja) * | 2016-09-30 | 2019-10-17 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 組織指向性発現を用いた抗体ベースの遺伝子治療 |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| CN109265559B (zh) * | 2018-09-25 | 2021-12-07 | 山东兴瑞生物科技有限公司 | 嵌合抗原受体、其制备方法、利用其修饰的nk细胞及治疗hbv感染的应用 |
| JP7588586B2 (ja) * | 2018-12-19 | 2024-11-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023545135A (ja) * | 2020-10-12 | 2023-10-26 | グレフェックス， インコーポレイテッド | ＳＡＲＳ－ＣｏＶタンパク質発現細胞に対するＴ細胞応答を標的にする抗体コンストラクト、それらの設計および使用 |
| CN112592902B (zh) * | 2020-12-16 | 2022-03-29 | 熊猫乳品集团股份有限公司 | 一种生物活性肽aseppvldvkrpflc及其制备方法和应用 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN114573705B (zh) * | 2022-03-17 | 2024-05-14 | 杭州师范大学 | 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用 |
| CN119790067A (zh) * | 2022-06-27 | 2025-04-08 | 新加坡星汉德生物医药有限公司 | 乙肝表面抗原（HBsAg）/CD3双特性抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2634294A1 (en) | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| DK1709081T3 (da) * | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| PT2155783E (pt) * | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| KR101589759B1 (ko) * | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| US8999398B2 (en) * | 2009-11-06 | 2015-04-07 | Transtarget Inc. | Polyclonal bispecific antibody compositions and method of use |
| EP2524699A1 (en) * | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| US9750806B2 (en) * | 2011-05-17 | 2017-09-05 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| CA2862448A1 (en) * | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| CN105636982B (zh) | 2013-09-16 | 2020-06-23 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） | 用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽 |
-
2014
- 2014-09-16 CN CN201480050976.8A patent/CN105636982B/zh active Active
- 2014-09-16 JP JP2016542337A patent/JP6599338B2/ja active Active
- 2014-09-16 CN CN202010449532.9A patent/CN111606998B/zh active Active
- 2014-09-16 RU RU2016114504A patent/RU2671089C2/ru active
- 2014-09-16 CA CA2924252A patent/CA2924252C/en active Active
- 2014-09-16 WO PCT/EP2014/069675 patent/WO2015036606A1/en not_active Ceased
- 2014-09-16 ES ES14771250T patent/ES2773306T3/es active Active
- 2014-09-16 US US15/021,916 patent/US10059767B2/en active Active
- 2014-09-16 EP EP14771250.9A patent/EP3046938B1/en active Active
-
2018
- 2018-08-24 US US16/112,431 patent/US10730943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530889A5 (enExample) | ||
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| CN112437776B (zh) | 间皮素和cd137结合分子 | |
| US9828432B2 (en) | Cancer treatment and monitoring methods using OX40 agonists | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| JP2018501197A5 (enExample) | ||
| JP2020526211A5 (enExample) | ||
| KR20210031479A (ko) | Cd137 및 ox40에 결합하는 항체 분자 | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2018508483A5 (enExample) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| JP2018512170A5 (enExample) | ||
| CN116003608A (zh) | 拮抗性cd40单克隆抗体及其用途 | |
| JP2016527286A5 (enExample) | ||
| HK1254289A1 (zh) | 调控免疫反应的方法及抗体 | |
| JP7650351B2 (ja) | 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 | |
| EP3843849A1 (en) | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JP2020532304A5 (enExample) | ||
| US20240011046A1 (en) | Oncolytic viruses encoding recombinant transforming growth factor (tgf)-beta monomers and uses thereof | |
| Zhang et al. | Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy | |
| Long et al. | HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | |
| Mendoza-Valderrey et al. | Next generation immuno-oncology strategies: unleashing NK cells activity | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| Palmeri et al. | Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy |